Concepedia
Statistics
Publications
152
Citations
10.9K
H-Index
47
Active since
2006
Affiliations
City of Hope(Current)
City Of Hope National Medical Center
Dana-Farber Cancer Institute
The University of Texas MD Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Alex F. Herrera is an author at City of Hope specializing in medicine, oncology, and immunotherapy.
Publications per year
2006–2025
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.3K citations
Medicine, Oncology, Pharmacology +12
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology · 2019 · 772 citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Caron A. Jacobson, Bradley D. Hunter, Robert Redd et al. · Journal of Clinical Oncology · 2020 · 345 citations · Full text
Medicine, Oncology, Pharmacology +17
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett et al. · Blood · 2017 · 320 citations · Full text
Medicine, Hematology, Oncology +15
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S. Neelapu, Michael Dickinson, Javier Muñoz et al. · Nature Medicine · 2022 · 283 citations · Full text
Medicine, Hematology, Oncology +17
1–5 of 152